Lansforsakringar Fondforvaltning AB publ Takes $267,000 Position in argenx SE (NASDAQ:ARGX)

Lansforsakringar Fondforvaltning AB publ bought a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 434 shares of the company's stock, valued at approximately $267,000.

Other hedge funds have also recently bought and sold shares of the company. Point72 Europe London LLP acquired a new stake in shares of argenx in the fourth quarter valued at approximately $5,839,000. Stephens Inc. AR acquired a new stake in shares of argenx in the fourth quarter valued at approximately $310,000. Jones Financial Companies Lllp raised its holdings in shares of argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of argenx by 10.0% in the fourth quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock valued at $4,313,000 after purchasing an additional 639 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of argenx by 47.8% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 1,776 shares of the company's stock valued at $1,092,000 after purchasing an additional 574 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ARGX shares. William Blair reiterated an "outperform" rating on shares of argenx in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $720.00 price objective on shares of argenx in a report on Tuesday, April 8th. Guggenheim decreased their target price on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Oppenheimer raised their target price on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Baird R W raised shares of argenx from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $709.18.

argenx Price Performance

Shares of NASDAQ:ARGX traded down $4.21 during trading on Friday, reaching $576.74. 350,163 shares of the stock were exchanged, compared to its average volume of 323,478. argenx SE has a 1-year low of $368.57 and a 1-year high of $678.21. The stock has a fifty day moving average of $586.57 and a two-hundred day moving average of $612.52. The firm has a market cap of $35.22 billion, a price-to-earnings ratio of -655.39 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. Sell-side analysts forecast that argenx SE will post 3.13 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.